Publication:

Cystatin C deficiency in human atherosclerosis and aortic aneurysms

Loading...
Thumbnail Image

Date

1999

Published Version

Journal Title

Journal ISSN

Volume Title

Publisher

American Society for Clinical Investigation
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Shi, Guo-Ping, Galina K. Sukhova, Anders Grubb, Anique Ducharme, Luis H. Rhode, Richard T. Lee, Paul M. Ridker, Peter Libby, and Harold A. Chapman. 1999. “Cystatin C Deficiency in Human Atherosclerosis and Aortic Aneurysms.” J. Clin. Invest. 104 (9) (November 1): 1191–1197. doi:10.1172/jci7709.

Abstract

The pathogenesis of atherosclerosis and abdominal aortic aneurysm involves breakdown of the elastic laminae. Elastolytic cysteine proteases, including cathepsins S and K, are overexpressed at sites of arterial elastin damage, but whether endogenous local inhibitors counterbalance these proteases is unknown. We show here that, whereas cystatin C is normally expressed in vascular wall smooth muscle cells (SMCs), this cysteine protease inhibitor is severely reduced in both atherosclerotic and aneurysmal aortic lesions. Furthermore, increased abdominal aortic diameter among 122 patients screened by ultrasonography correlated inversely with serum cystatin C levels. In vitro, cytokine-stimulated vascular SMCs secrete cathepsins, whose elastolytic activity could be blocked when cystatin C secretion was induced by treatment with TGF-β1. The findings highlight a potentially important role for imbalance between cysteine proteases and cystatin C in arterial wall remodeling and establish that cystatin C deficiency occurs in vascular disease.

Description

Research Data

Keywords

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Related Stories